Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients

Journal of Zhejiang University: Science

Volumn 6 B, Issue 9, 2005, Pages 885-891

  Lu, Xiao Yang ^a   Huang, Hong Feng ^a   Shentu, Jian Zhong ^a   Liu, Jian ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Kidney transplant; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetics

Indexed keywords

DRUG PRODUCTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHARMACOKINETICS; TRANSPLANTATION (SURGICAL);

CYCLOSPORIN A (CSA); KIDNEY TRANSPLANT PATIENTS; MYCOPHENOLATE MOFETIL (MMF); MYCOPHENOLIC ACID (MPA); PHARMACEUTICAL KINETICS SOFTWARE (PKS); SOFTWARE PACKAGE; TACROLIMUS (FK506);

DRUG THERAPY;

CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 26844463990     PISSN: 10093095     EISSN: None     Source Type: Journal    
DOI: 10.1631/jzus.2005.B0885     Document Type: Article

References (22)

1. Bullingham, R.E., Nicholls, A., Hale, M., 1996a. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant. Proc., 28(2): 925-929.
2. Bullingham, R.E., Monroe, S., Nicholls, A., Hale, M., 1996b. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. din. Pharmacol., 36(4): 315-324.
3. Bullingham, R.E., Nicholls, A.J., Kamm, B.R., 1998. Pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet., 34(6): 429-455.
4. Cho, E.K., Han, D.J., Kim, S.C., Burckart, G.J., Venkataramanan, R., Oh, J.M., 2004. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J. Clin. Pharmacol., 44(7): 743-750.
5. European Mycophenolate Mofetil Cooperative Study Group, 1995. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet., 345(8961): 1321-1325.
6. Filler, G., Zimmering, M., Mai, I., 2000. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr. Nephrol., 14(2): 100-104.
7. Gregoor, P.J., de Sevaux, R.G., Hene, R.J., Hesse, C.J., Hilbrands, E.B., Vos, P., van Gelder, T., Hoitsma, A.J., Weimar, W., 1999. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation, 68(10): 1603-1606.
8. Johnson, A.G., Rigby, R.J., Taylor, P.J., Jones, C.E., Alien, J., Franzen, K., Falk, M.C., Nicol, D., 1999. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin. Pharmacol. Ther., 66(5): 492-500.
9. Kuriata-kordek, M., Boratynska, M., Falkiewicz, K., Porazko, T., Urbaniak, J., Wozniak, M., Patrzalek, D., Szyber, P., Klinger, M., 2003. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant. Proc., 35(6): 2369-2371.
10. Lee, H.J., Pawlak, K., Nguyen, B.T., Robinsm, R.K., Sadee, W., 1985. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studies in mouse lymphoma cell culture. Cancer Res., 45: 5512-5520.
11. Matsuzawa, Y., Nakase, T., 1984. Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals. J. Pharmacobiodyn., 7(10): 776-783.
12. Pescovitz, M.D., Guasch, A., Gaston, R., Rajagopalan, P., Tomlanovich, S., Weinstein, S., Bumgardner, G.L., Melton, L., Ducray, P.S., Banken, L., et al, 2003. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am. J. Transplant., 3(12): 1581-1586.
13. Rasom, J.T., 1995. Mechanism of action of mycophenolate mofetil. Ther. Drug. Monit., 17(6): 681-684.
14. Shaw, E.M., Sollinger, H.W., Halloran, P., Morris, R.E., Yatscoff, R.W., Ransom, J., Tsina, I, Keown, P., Holt, D.W., Lieberman, R., 1995. Mycophenolate mofetil: A report of the consensus panel. Ther. Drug. Monit., 17(6): 690-699.
15. Shaw, L.M., Nicholl, A., Hale, M., Armstrong, V.W., Oellerich, M., Yatscoff, R., Morris, R.E., Holt, D.W., Venkataramanan, R., Haley, J., et al., 1998. Therapeutic monitoring of mycophenolic acid: A consensus panel report. Clin. Biochem., 31(5): 317-322.
16. Shaw, L.M., Kaplan, B., DeNofrio, D., Korecka, M., Brayman, K.L., 2000. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther. Drug. Monit., 22(1): 14-19.
17. Shaw, L.M., Pawinski, T., Korecka, M., Nawrocki, A., 2002. Monitoring of mycophenolic acid in clinical transplantation. Ther. Drug. Monit., 24(1): 68-73.
18. Takahashi, K., Ochiai, T., Uchida, K., Yasumara, T., Ishibashi, M., Suzuki, S., Otsubo, O., Isono, K., Takagi, H., Oka, T., 1995. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee-Japan. Transplant. Proc., 27(1): 1421-1424.
19. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, 1996. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation, 61(7): 1029-1037.
20. Young, C.J., Sollinger, H.W., 1994. RS-61443: A new immunosuppressive agent. Transplant. Proc., 26(6): 3144-3146.
21. Zucker, K., Rosen, A., Tsaroucha, A., de Faria, L., Roth, D., Ciancio, G., Esquenazi, V., Burke, G., Tzakis, A., Miller, J., 1997. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mucophenolate mofetil in combination therapy, an analogous in vitro findings. Transpl. Immunol., 5(3): 225-232.
22. Zucker, K., Tsaroucha, A., Olsen, L., Esquenazi, V., Tzakis, A., Miller, J., 1999. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther. Drug. Monit., 21(1): 35-43.